These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 23281407)

  • 21. Hypercholesterolemia Induced Immune Response and Inflammation on Progression of Atherosclerosis in Apob(tm2Sgy) Ldlr(tm1Her)/J Mice.
    Rao LN; Ponnusamy T; Philip S; Mukhopadhyay R; Kakkar VV; Mundkur L
    Lipids; 2015 Aug; 50(8):785-97. PubMed ID: 26178198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inflammation and immune system contribution to the etiology of atherosclerosis: mechanisms and methods of assessment.
    Salisbury D; Bronas U
    Nurs Res; 2014; 63(5):375-85. PubMed ID: 25171563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The immune system in atherosclerosis.
    Hansson GK; Hermansson A
    Nat Immunol; 2011 Mar; 12(3):204-12. PubMed ID: 21321594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of natural antibodies in atherogenesis.
    Binder CJ; Shaw PX; Chang MK; Boullier A; Hartvigsen K; Hörkkö S; Miller YI; Woelkers DA; Corr M; Witztum JL
    J Lipid Res; 2005 Jul; 46(7):1353-63. PubMed ID: 15897601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease.
    Gounopoulos P; Merki E; Hansen LF; Choi SH; Tsimikas S
    Minerva Cardioangiol; 2007 Dec; 55(6):821-37. PubMed ID: 18091649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inflammation in atherosclerosis.
    Libby P
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2045-51. PubMed ID: 22895665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complement and atherosclerosis-united to the point of no return?
    Torzewski M; Bhakdi S
    Clin Biochem; 2013 Jan; 46(1-2):20-5. PubMed ID: 23010447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HDL and immunomodulation: an emerging role of HDL against atherosclerosis.
    Yu BL; Wang SH; Peng DQ; Zhao SP
    Immunol Cell Biol; 2010; 88(3):285-90. PubMed ID: 20065996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL.
    Navab M; Ananthramaiah GM; Reddy ST; Van Lenten BJ; Ansell BJ; Fonarow GC; Vahabzadeh K; Hama S; Hough G; Kamranpour N; Berliner JA; Lusis AJ; Fogelman AM
    J Lipid Res; 2004 Jun; 45(6):993-1007. PubMed ID: 15060092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxidation-specific epitopes are important targets of innate immunity.
    Chou MY; Hartvigsen K; Hansen LF; Fogelstrand L; Shaw PX; Boullier A; Binder CJ; Witztum JL
    J Intern Med; 2008 May; 263(5):479-88. PubMed ID: 18410591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the adaptive immune system: new strategies in the treatment of atherosclerosis.
    Zarzycka B; Nicolaes GA; Lutgens E
    Expert Rev Clin Pharmacol; 2015 May; 8(3):297-313. PubMed ID: 25843158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendritic cells in atherosclerosis.
    Cartland SP; Jessup W
    Curr Pharm Des; 2013; 19(33):5883-90. PubMed ID: 23438964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atherogenesis and inflammation. From cellular mediators to regulatory mechanisms of inflammation in atherosclerosis.
    Weber C; Hristov M
    Hamostaseologie; 2015; 35(2):99, 101. PubMed ID: 25943077
    [No Abstract]   [Full Text] [Related]  

  • 34. Antigen-tailored therapy based on the inflammatory theory of atherosclerosis.
    Harats D; George J
    Expert Rev Vaccines; 2004 Oct; 3(5):605-11. PubMed ID: 15485340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The therapeutic potential of targeting B cells and anti-oxLDL antibodies in atherosclerosis.
    van Leeuwen M; Damoiseaux J; Duijvestijn A; Tervaert JW
    Autoimmun Rev; 2009 Sep; 9(1):53-7. PubMed ID: 19285155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune-mediated mechanisms of atherosclerosis and implications for the clinic.
    Nus M; Mallat Z
    Expert Rev Clin Immunol; 2016 Nov; 12(11):1217-1237. PubMed ID: 27253721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulatory T cells and the control of modified lipoprotein autoimmunity-driven atherosclerosis.
    Nilsson J; Wigren M; Shah PK
    Trends Cardiovasc Med; 2009 Nov; 19(8):272-6. PubMed ID: 20447570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibodies against oxidized low-density lipoprotein for the treatment of vulnerable plaques.
    Nilsson J; Glazer S; Carlsson R
    Curr Opin Investig Drugs; 2006 Sep; 7(9):815-9. PubMed ID: 17002259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early atherogenesis: new insights from new approaches.
    Scipione CA; Cybulsky MI
    Curr Opin Lipidol; 2022 Oct; 33(5):271-276. PubMed ID: 35979994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendritic cells in atherosclerosis: functions in immune regulation and beyond.
    Manthey HD; Zernecke A
    Thromb Haemost; 2011 Nov; 106(5):772-8. PubMed ID: 21901235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.